Page last updated: 2024-09-03

sch 23982 and butaclamol

sch 23982 has been researched along with butaclamol in 2 studies

Compound Research Comparison

Studies
(sch 23982)
Trials
(sch 23982)
Recent Studies (post-2010)
(sch 23982)
Studies
(butaclamol)
Trials
(butaclamol)
Recent Studies (post-2010) (butaclamol)
870023332

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, EF; Fahlbusch, R; Nomikos, P; Reif, M; Schrell, UM1
Caron, MG; Charpentier, S; Jarvie, KR; Severynse, DM; Tiberi, M1

Other Studies

2 other study(ies) available for sch 23982 and butaclamol

ArticleYear
Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.
    The Journal of clinical endocrinology and metabolism, 1990, Volume: 71, Issue:6

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Apomorphine; Benzazepines; Binding, Competitive; Bromocriptine; Butaclamol; Cell Division; Dopamine; Dopamine Agents; Humans; Meningioma; Receptors, Dopamine; Receptors, Dopamine D1; Tumor Cells, Cultured

1990
Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties.
    The Journal of biological chemistry, 1996, Nov-08, Volume: 271, Issue:45

    Topics: Adenylyl Cyclases; Arginine; Benzazepines; Binding, Competitive; Butaclamol; Cyclic AMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoleucine; Models, Molecular; Phenylalanine; Protein Conformation; Receptors, Dopamine D1; Receptors, Dopamine D5; Structure-Activity Relationship

1996